Figure 5
From: The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF
FLX acts on energy balance and leptin sensitivity in animals exposed to high fat diet. (A) Weight gain with respect to start of FLX treatment for H2O-HFD and FLX-HFD mice. RM 2-way ANOVA (time effect, F(2,54) = 30.18, P < 0.0001; matching, F(27,54) = 1.85, P = 0.027; n = 24–27) followed by Bonferroni posthoc test, *P < 0.05. (B) Body weight at the end of the treatment in H2O-HFD and FLX-HFD mice. Student’s t-test (t = 3.02 df = 34, **P = 0.0048; n = 18). (C) Weight of white fat depots (EPI, SC and PERI) in H2O-HFD and FLX-HFD mice. Student’s t-test (EPI WAT t = 2.932 df = 31, **P = 0.0063; PERI WAT t = 2.169 df = 31, *P = 0.038; n = 15–18). (D) Food intake in H2O-HFD and FLX-HFD; the arrow indicates the start of FLX treatment and each point represents a daily average per week (n = 24–27). (E) Daily total energy expenditure of H2O-HFD and FLX-HFD mice measured by doubly labelled water method. Student’s t-test (t = 5.885 df = 17, ***P < 0.0001; n = 10–9). (F) Infrared locomotor activity monitoring assessed in H2O-HFD and FLX-HFD mice (number of animals = 6; n = 100). Mann Whitney test (**P = 0.0073). (G) Plasma leptin in H2O-HFD and FLX-HFD mice. Student’s t-test (t = 2.428 df = 15, *P = 0.028; n = 8–9). (H) 14 hours cumulative food intake in H2O-HFD and FLX-HFD mice at baseline and in response to i.p. leptin (3 mg/kg) injection (n = 11–7). (I) Left, representative immunofluorescence showing expression of pSTAT3 45’ after an injection of saline (sal) or leptin (lep, 3 mg/kg) in the ARC of H2O-HFD and FLX-HFD. Scale bar is 100 μm. Right, signal for pSTAT3 normalized to that of STAT3 was acquired in H2O-HFD and FLX-HFD mice. All data are expressed as % of the mean of the H2O-HFD injected with saline. 2-way ANOVA (treatment × stimulus, F(1,12) = 14.78, P = 0.0023; n = 3) followed by Bonferroni posthoc test, *P < 0.05 versus H2O, §§§P < 0.001 versus saline. Data are presented as mean ± s.e.m.
